173 related articles for article (PubMed ID: 37923056)
41. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Monk BJ; Poveda A; Vergote I; Raspagliesi F; Fujiwara K; Bae DS; Oaknin A; Ray-Coquard I; Provencher DM; Karlan BY; Lhommé C; Richardson G; Rincón DG; Coleman RL; Herzog TJ; Marth C; Brize A; Fabbro M; Redondo A; Bamias A; Tassoudji M; Navale L; Warner DJ; Oza AM
Lancet Oncol; 2014 Jul; 15(8):799-808. PubMed ID: 24950985
[TBL] [Abstract][Full Text] [Related]
42. Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer.
Singh N; Jayraj AS; Sarkar A; Mohan T; Shukla A; Ghatage P
Expert Opin Pharmacother; 2023 Jan; 24(1):49-64. PubMed ID: 35968667
[TBL] [Abstract][Full Text] [Related]
43. Living Through Ovarian Cancer Treatment: Acute and Long-Term Toxicities of Chemotherapy for Advanced-Stage Disease.
Gockley A; Wright A
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1073-1085. PubMed ID: 30390761
[TBL] [Abstract][Full Text] [Related]
44. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Harter P; Pautier P; Van Nieuwenhuysen E; Reuss A; Redondo A; Lindemann K; Kurzeder C; Petru E; Heitz F; Sehouli J; Degregorio N; Wimberger P; Burges A; Cron N; Ledermann J; Lorusso D; Paoletti X; Marme F
Int J Gynecol Cancer; 2020 Dec; 30(12):1997-2001. PubMed ID: 32606097
[TBL] [Abstract][Full Text] [Related]
45. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
46. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
47. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
48. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
49. Anti-angiogenic agents in ovarian cancer: dawn of a new era?
Liu J; Matulonis UA
Curr Oncol Rep; 2011 Dec; 13(6):450-8. PubMed ID: 21993845
[TBL] [Abstract][Full Text] [Related]
50. Metronomic chemotherapy for advanced breast cancer patients.
Cazzaniga ME; Dionisio MR; Riva F
Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
[TBL] [Abstract][Full Text] [Related]
51. Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Ventriglia J; Paciolla I; Cecere SC; Pisano C; Di Napoli M; Arenare L; Setola SV; Losito NS; Califano D; Orditura M; Pignata S
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):498-503. PubMed ID: 29429842
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
53. Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions.
Vetter MH; Hays JL
Clin Ther; 2018 Mar; 40(3):361-371. PubMed ID: 29482922
[TBL] [Abstract][Full Text] [Related]
54. Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies.
Leung SOA; Konstantinopoulos PA
Expert Opin Investig Drugs; 2021 Jul; 30(7):695-707. PubMed ID: 34082614
[No Abstract] [Full Text] [Related]
55. Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C; Charakorn C; Chittithaworn S; Lertkhachonsuk AA
J Obstet Gynaecol; 2022 Aug; 42(6):2331-2335. PubMed ID: 35470751
[TBL] [Abstract][Full Text] [Related]
56. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
Gupta S; Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2019 Nov; 12(1):103. PubMed ID: 31685032
[TBL] [Abstract][Full Text] [Related]
57. Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma.
Rose PG; Roma A
Anticancer Drugs; 2013 Oct; 24(9):986-8. PubMed ID: 23872910
[TBL] [Abstract][Full Text] [Related]
58. Combining targeted therapies in ovarian cancer.
Scambia G; Salutari V; Ferrandina G
Lancet Oncol; 2014 Oct; 15(11):1179-81. PubMed ID: 25218905
[No Abstract] [Full Text] [Related]
59. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
60. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
